Oramed wins European patent for insulin pill tech

Israel's Oramed ($ORMP) won a patent from the European Union for its oral insulin pill, giving the Jerusalem company a potential foothold in the diabetes market estimated to be worth about $14 billion by 2017, according to analysts. The patent covers Oramed's process for the oral administration of proteins. The company's main insulin pill is currently in Phase II trials for Type 2 diabetes, and its oral exanatide capsule, also for Type 2, is in early clinical stages. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…